FDA Launches Pilot Program to Speed Early Clinical Trials
The FDA's Expedited Investigational New Drug (IND) Pilot pairs drug sponsors with research institutions to reduce startup delays for early human studies.
Tag: clinical trials
All
Latest
FDA Launches Pilot Program to Speed Early Clinical Trials
The FDA’s Expedited Investigational New Drug (IND) Pilot pairs drug sponsors with research institutions to reduce startup delays for early human studies.
Read More
ALA Expands Lung Cancer Clinical Trial Awareness
The American Lung Association initiative seeks to address mistrust, reduce disparities, and expand lung cancer trial participation among underrepresented patient populations.
Read More
Oral Bacterial Extract Fails to Prevent Asthma in High-Risk Children
A multiyear clinical trial found that OM-85 did not reduce severe wheezing episodes or early childhood asthma diagnoses.
Read More
Asthma Antiviral Nasal Spray Secures Funding for Clinical Trial
A clinical trial will evaluate a weekly dry powder nasal spray’s ability to boost natural defenses and prevent asthma infections.
Read More
Study to Evaluate Effectiveness of Brensocatib for Bronchiectasis
The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
Read More
Invenio Imaging Completes Enrollment for Ai Lung Cancer Biopsy Study
The multicenter study will evaluate an artificial intelligence module designed for rapid tissue assessment during bronchoscopic procedures.
Read More
Duchenne Muscular Dystrophy Cell Therapy Preserves Heart, Muscle Function
Results from the HOPE-3 trial found that an investigational cell therapy called deramiocel preserved heart and muscle function in boys and young men with Duchenne muscular dystrophy (DMD).
Read More
Twice-yearly COPD Biologic Begins Trial
Windward Bio is evaluating WIN378, a monoclonal antibody designed for twice-yearly dosing in patients with moderate-to-severe COPD.
Read More
Alpha-1 Antitrypsin Deficiency Drug Enters Ph3 Trial
Grifols enrolled the first patient in its Phase 3 SWIFT-SC clinical trial to evaluate its subcutaneous Alpha1-Proteinase Inhibitor for the treatment of alpha1-antitrypsin (AAT) deficiency.
Read More
RSV Antiviral Zelicapavir Enters Late-stage Clinical Trials
Enanta Pharma advanced zelicapavir into a registrational Phase 2b/3 clinical trial for adults at high risk of severe RSV outcomes.
Read More
Ai-Generated Drug Rentosertib Trialed for Idiopathic Pulmonary Fibrosis
Insilico Medicine initiated a Phase 3 clinical trial for Rentosertib, an oral medication discovered using artificial intelligence to treat idiopathic pulmonary fibrosis (IPF).
Read More
Positive Data for Inhaled Pulmonary Arterial Hypertension Treatment
Once-daily treprostinil palmitil inhalation powder improved exercise capacity and reduced mortality risk for pulmonary arterial hypertension.
Read More
Inhaled Molgramostim Improved Exercise Capacity
Phase 3 clinical trial data shows improvements in walking distance and duration for patients with autoimmune pulmonary alveolar proteinosis treated with inhaled molgramostim.
Read More
Ralinepag Reduced Pulmonary Arterial Hypertension Progression
Phase 3 trial results show ralinepag significantly reduced the risk of worsening symptoms and improved exercise capacity in pulmonary arterial hypertension patients.
Read More
Nebulized Treprostinil Preserved IPF Lung Function
Phase 3 trial results show significant reductions in clinical worsening and acute exacerbations for patients with idiopathic pulmonary fibrosis (IPF).
Read More
Inhaled Nitric Oxide Therapy Alx1 Well Tolerated in Ph1 Trial
Phase 1 data for the investigational inhaled nitric oxide therapy Alx1 demonstrated the treatment was well tolerated with no serious side effects in healthy volunteers.
Read More
Nebulized Dual Bronchodilator Aero-007 Improved COPD Lung Function
AERO-007 demonstrated significant lung function improvements over 24 hours in patients with moderate-to-severe COPD.
Read More
Alpha-1 Drug Candidate Superior to Standard Care
Phase 2 data for efdoralprin alfa demonstrate the recombinant protein maintains normal protein levels with less frequent dosing than current standards of care for patients with alpha-1 antitrypsin deficiency (AATD)-related emphysema.
Read More
Tezepelumab Reduced Asthma Attacks
A new study shows tezepelumab (Tezspire) reduced asthma exacerbations by 70% across all patient subgroups, including smokers and those with comorbid conditions.
Read More
Enanta Pharma to Present Data for RSV, STAT6 Therapies at ATS 2026
Enanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read More
New Data on Inhaled Treprostinil for IPF
Data from clinical trials investigating treatments for pulmonary hypertension and pulmonary fibrosis will be highlighted at ATS 2026.
Read More
Phase II Trial for Antiviral Nasal Spray Advances to Next Stage
The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read More
ALA Launches Study to Test Omalizumab for COPD Flare-ups
The COPD-OMA trial will examine if the asthma drug omalizumab (Xolair) benefits COPD patients with sensitivities to indoor allergens.
Read More
Tozorakimab Reduces COPD Flare-Ups in Ph3 Trial
The MIRANDA study found tozorakimab significantly lowered the rate of moderate-to-severe respiratory worsening in patients regardless of smoking history or specific white blood cell counts.
Read More